CYP2C19 and transient ischemic attack: CHANCE-2 [49] was a double-blind, placebo-controlled RCT that compared ticagrelor plus aspirin to clopidogrel plus aspirin in carriers of the CYP2C19 loss-of-function mutation that presented with minor ischemic stroke or TIA.